(S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-2,5-dioxopentyl 2,6-dichlorobenzoate | 1356848-28-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-2,5-dioxopentyl 2,6-dichlorobenzoate
• CAS: 1356848-28-6
• 化学式: C₃₁H₂₉Cl₂NO₇
• 分子量: 598.48
• InChiKey: XTRHSMUAMGHZOK-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.36
• 重原子数：
  41.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  108.0
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-2,5-dioxopentyl 2,6-dichlorobenzoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 以19.1 g的产率得到(3S)-5-(2,6-dichlorobenzoyl)oxy-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxopentanoic acid
  参考文献：
  名称：

  Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors

  摘要：

  Because of their central role in programmed cell death, the caspases are attractive targets for developing new therapeutics against cancer and autoimmunity, myocardial infarction and ischemic damage, and neurodegenerative diseases. We chose to target caspase-3, an executioner caspase, and caspase-8, an initiator caspase, based on the vast amount of information linking their functions to diseases. Through a structure-based drug design approach, a number of novel beta-strand peptidomimetic compounds were synthesized. Kinetic studies of caspase-3 and caspase-8 inhibition were carried out with these urazole ring-containing irreversible peptidomimetics and a known irreversible caspase inhibitor, Z-VAD-fmk. Using a stopped-flow fluorescence assay, we were able to determine individual kinetic parameters of caspase-3 and caspase-8 inhibition by these inhibitors. Z-VAD-fmk and the peptidomimetic inhibitors inhibit caspase-3 and caspase-8 via a three-step kinetic mechanism. Inhibition of both caspase-3 and caspase-8 by Z-VAD-fmk and of caspase-3 by the peptidomimetic inhibitors proceeds via two rapid equilibrium steps followed by a relatively fast inactivation step. However, caspase-8 inhibition by the peptidomimetics goes through a rapid equilibrium step, a slow-binding reversible step, and an extremely slow inactivation step. The crystal structures of inhibitor complexes of caspases-3 and -8 validate the design of the inhibitors by illustrating in detail how they mimic peptide substrates. One of the caspase-8 structures also shows binding at a secondary, allosteric site, providing a possible route to the development of noncovalent small molecule modulators of caspase activity. (C) 2010 Published by Elsevier B.V.

  DOI：

  10.1016/j.bbapap.2010.05.007
• 作为产物：
  描述：

  Fmoc-L-天冬氨酸 beta-叔丁酯 在 N-甲基吗啉 、 氢溴酸 、 碳酸氢钠 、 potassium iodide 作用下， 以 四氢呋喃 、 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.67h， 生成 (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-2,5-dioxopentyl 2,6-dichlorobenzoate
  参考文献：
  名称：

  Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors

  摘要：

  Because of their central role in programmed cell death, the caspases are attractive targets for developing new therapeutics against cancer and autoimmunity, myocardial infarction and ischemic damage, and neurodegenerative diseases. We chose to target caspase-3, an executioner caspase, and caspase-8, an initiator caspase, based on the vast amount of information linking their functions to diseases. Through a structure-based drug design approach, a number of novel beta-strand peptidomimetic compounds were synthesized. Kinetic studies of caspase-3 and caspase-8 inhibition were carried out with these urazole ring-containing irreversible peptidomimetics and a known irreversible caspase inhibitor, Z-VAD-fmk. Using a stopped-flow fluorescence assay, we were able to determine individual kinetic parameters of caspase-3 and caspase-8 inhibition by these inhibitors. Z-VAD-fmk and the peptidomimetic inhibitors inhibit caspase-3 and caspase-8 via a three-step kinetic mechanism. Inhibition of both caspase-3 and caspase-8 by Z-VAD-fmk and of caspase-3 by the peptidomimetic inhibitors proceeds via two rapid equilibrium steps followed by a relatively fast inactivation step. However, caspase-8 inhibition by the peptidomimetics goes through a rapid equilibrium step, a slow-binding reversible step, and an extremely slow inactivation step. The crystal structures of inhibitor complexes of caspases-3 and -8 validate the design of the inhibitors by illustrating in detail how they mimic peptide substrates. One of the caspase-8 structures also shows binding at a secondary, allosteric site, providing a possible route to the development of noncovalent small molecule modulators of caspase activity. (C) 2010 Published by Elsevier B.V.

  DOI：

  10.1016/j.bbapap.2010.05.007